Effect of Combination Treatment of Rapamycin and Isoflavones on MTOR Pathway in Human Glioblastoma (U87) Cells

Overview

Journal Neurochem Res

Specialties Chemistry
Neurology

Date 2010 Feb 24

PMID 20177775

Citations 15

Authors

Shilpa Puli

Aditi Jain

James C K Lai

Alok Bhushan

Affiliations

Soon will be listed here.

Abstract

Glioblastoma Multiforme (GBM) is a malignant primary brain tumor associated with poor survival rate. PI3K/Akt pathway is highly upregulated in gliomas due to deletion or mutation of PTEN and its activation is associated with tumor grade. mTOR is downstream from PI3K/Akt pathway and it initiates translation through its action on S6K and 4E-BP1. mTOR is an important therapeutic target in many cancers, including glioblastomas. Rapamycin and its analogues are known to inhibit mTOR pathway; however, they also show simultaneous upregulation of Akt and eIF4E survival pathways on inhibition of mTOR, rendering cells more resistant to rapamycin treatment. In this study we investigated the effect of combination treatment of rapamycin with isoflavones such as genistein and biochanin A on mTOR pathway and activation of Akt and eIF4E in human glioblastoma (U87) cells. Our results show that combination treatment of rapamycin with isoflavones, especially biochanin A at 50 muM, decreased the phosphorylation of Akt and eIF4E proteins and rendered U87 cells more sensitive to rapamycin treatment when compared to cells treated with rapamycin alone. These results suggest the importance of combining chemopreventive with chemotherapeutic agents in order to increase the efficacy of chemotherapeutic drugs.

Citing Articles

A novel approach to glioblastoma multiforme treatment using modulation of key pathways by naturally occurring small molecules.

Afshari A, Sanati M, Aminyavari S, Keshavarzi Z, Ahmadi S, Oroojalian F Inflammopharmacology. 2025; .

PMID: 39955698 DOI: 10.1007/s10787-025-01666-5.

Anticancer Mechanism of Flavonoids on High-Grade Adult-Type Diffuse Gliomas.

Wong S, Kamarudin M, Naidu R Nutrients. 2023; 15(4).

PMID: 36839156 PMC: 9964830. DOI: 10.3390/nu15040797.

Mutations in Glioma: Double-Edged Sword in Clinical Applications?.

Kayabolen A, Yilmaz E, Bagci-Onder T Biomedicines. 2021; 9(7).

PMID: 34356864 PMC: 8301439. DOI: 10.3390/biomedicines9070799.

Current Perspective on the Natural Compounds and Drug Delivery Techniques in Glioblastoma Multiforme.

Behl T, Sharma A, Sharma L, Sehgal A, Singh S, Sharma N Cancers (Basel). 2021; 13(11).

PMID: 34199460 PMC: 8199612. DOI: 10.3390/cancers13112765.

Anti-neoplastic Potential of Flavonoids and Polysaccharide Phytochemicals in Glioblastoma.

Atiq A, Parhar I Molecules. 2020; 25(21).

PMID: 33113890 PMC: 7660188. DOI: 10.3390/molecules25214895.

References

Masri J, Bernath A, Martin J, Jo O, Vartanian R, Funk A . mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res. 2007; 67(24):11712-20. DOI: 10.1158/0008-5472.CAN-07-2223. View

Tremont-Lukats I, Gilbert M . Advances in molecular therapies in patients with brain tumors. Cancer Control. 2003; 10(2):125-37. DOI: 10.1177/107327480301000204. View

Rice L, Samedi V, Medrano T, Sweeney C, Baker H, Stenstrom A . Mechanisms of the growth inhibitory effects of the isoflavonoid biochanin A on LNCaP cells and xenografts. Prostate. 2002; 52(3):201-12. DOI: 10.1002/pros.10100. View

Doherty L, Gigas D, Kesari S, Drappatz J, Kim R, Zimmerman J . Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology. 2006; 67(1):156-8. DOI: 10.1212/01.wnl.0000223844.77636.29. View

Costa L, Gemmill R, Drabkin H . Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells. Urology. 2007; 69(3):596-602. DOI: 10.1016/j.urology.2007.01.053. View

Huang S, Houghton P . Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs. 2002; 3(2):295-304. View

Dutcher J . Mammalian target of rapamycin inhibition. Clin Cancer Res. 2004; 10(18 Pt 2):6382S-7S. DOI: 10.1158/1078-0432.CCR-050008. View

Paternot S, Roger P . Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation. Cancer Res. 2009; 69(11):4577-81. DOI: 10.1158/0008-5472.CAN-08-3260. View

Werzowa J, Cejka D, Fuereder T, Dekrout B, Thallinger C, Pehamberger H . Suppression of mTOR complex 2-dependent AKT phosphorylation in melanoma cells by combined treatment with rapamycin and LY294002. Br J Dermatol. 2009; 160(5):955-64. DOI: 10.1111/j.1365-2133.2008.08991.x. View

10.

Gingras A, Raught B, Sonenberg N . Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2001; 15(7):807-26. DOI: 10.1101/gad.887201. View

11.

Fotsis T, Pepper M, Adlercreutz H, Fleischmann G, Hase T, Montesano R . Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci U S A. 1993; 90(7):2690-4. PMC: 46161. DOI: 10.1073/pnas.90.7.2690. View

12.

Wong A, Bigner S, Bigner D, Kinzler K, Hamilton S, Vogelstein B . Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A. 1987; 84(19):6899-903. PMC: 299192. DOI: 10.1073/pnas.84.19.6899. View

13.

Reardon D, Quinn J, Vredenburgh J, Gururangan S, Friedman A, Desjardins A . Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res. 2006; 12(3 Pt 1):860-8. DOI: 10.1158/1078-0432.CCR-05-2215. View

14.

Sehdev V, Lai J, Bhushan A . Biochanin A Modulates Cell Viability, Invasion, and Growth Promoting Signaling Pathways in HER-2-Positive Breast Cancer Cells. J Oncol. 2010; 2009:121458. PMC: 2821773. DOI: 10.1155/2009/121458. View

15.

Cloughesy T, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S . Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008; 5(1):e8. PMC: 2211560. DOI: 10.1371/journal.pmed.0050008. View

16.

HARUTA T, Uno T, Kawahara J, Takano A, Egawa K, Sharma P . A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol. 2000; 14(6):783-94. DOI: 10.1210/mend.14.6.0446. View

17.

Hidalgo M, Rowinsky E . The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene. 2001; 19(56):6680-6. DOI: 10.1038/sj.onc.1204091. View

18.

Wendel H, de Stanchina E, Fridman J, Malina A, Ray S, Kogan S . Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 2004; 428(6980):332-7. DOI: 10.1038/nature02369. View

19.

Chen J, Fang Y . A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling. Biochem Pharmacol. 2002; 64(7):1071-7. DOI: 10.1016/s0006-2952(02)01263-7. View

20.

Gulati N, Karsy M, Albert L, Murali R, Jhanwar-Uniyal M . Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility. Int J Oncol. 2009; 35(4):731-40. DOI: 10.3892/ijo_00000386. View